Skip to main content
Caplight Logo









TILT Biotherapeutics

TILT Biotherapeutics

Private
HelsinkiHealthcare & Life Scienceshttps://tilt.bio/

Last Round

Series B

May 13, 2025

Total Funding Raised

$66.6M

Company Overview

TILT Biotherapeutics is a biotechnology company developing oncolytic immunotherapies to enable T-cell therapies for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oncolytic viruscancer immunotherapyimmuno-oncologyviral delivery platformoncolytic adenovirustumor microenvironmentclinical stage biotechimmune checkpoint inhibitorsbiotech licensingviral vectorcold tumor therapycancer drug developmentbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TILT Biotherapeutics Comparables

Compare TILT Biotherapeutics with similar companies based on industry and business-model similarity.

TILT Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Accession Therapeutics Limited
88%
Akamis Bio
85%
ORCA Therapeutics
85%

TILT Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 13, 2025
GrantFeb 7, 2023
Series AFeb 7, 2023
Series AJun 14, 2022
VC RoundJun 16, 2020
Seed
Dec 16, 2016

TILT Biotherapeutics Investors

Notable investors and investment history

TILT Biotherapeutics investors
InvestorRounds
European Innovation Council FundSeries B, Series A
TesiSeries B, Series A
Business FinlandVC Round
Lifeline VenturesSeries B, Seed, Series A
EIC AcceleratorGrant
TekesSeed
Stephen Industries Inc OySeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 3, 2026

    Web traffic grew 75% MoM (from 506 to 883 monthly visitors)

  • Mar 4, 2026

    Monthly visitors increased 61% MoM.

TILT Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TILT Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TILT Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHelsinki
Employee Range26
Year Founded2013
Last FundingMay 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?